Development of a Commercial Manufacturing Process for Vepdegestrant, an Orally Bioavailable PROTAC Estrogen Receptor Degrader for the Treatment of Breast Cancer
已完结10由 逸云 发布于 2025/2/28 14:30:14
DOI:10.1021/acs.oprd.4c00362
作者:Steve Avery, Jamie M. Buske, Doris Chen, Herman Chen, Xin Chen, Andrew R. Davidson, Jean-Nicolas Desrosiers, Hanqing Dong, Noalle Fellah, David F. Fernández, John Grosso, Lu Han, Teri Hochdorfer, Amb
文献类型:期刊论文
补充材料:只需要正文